KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sarepta Therapeutics (SRPT) EBT Margin (2017 - 2025)

Sarepta Therapeutics has reported EBT Margin over the past 12 years, most recently at 80.69% for Q4 2025.

  • For Q4 2025, EBT Margin rose 5461.0% year-over-year to 80.69%; the TTM value through Dec 2025 reached 3.03%, down 1674.0%, while the annual FY2025 figure was 3.03%, 1674.0% down from the prior year.
  • EBT Margin for Q4 2025 was 80.69% at Sarepta Therapeutics, up from 48.59% in the prior quarter.
  • Over five years, EBT Margin peaked at 123.81% in Q4 2021 and troughed at 2329.97% in Q1 2023.
  • A 5-year average of 229.19% and a median of 18.01% in 2023 define the central range for EBT Margin.
  • Biggest five-year swings in EBT Margin: plummeted -228057bps in 2023 and later soared 234000bps in 2024.
  • Year by year, EBT Margin stood at 123.81% in 2021, then tumbled by -84bps to 19.31% in 2022, then surged by 55bps to 29.85% in 2023, then decreased by -13bps to 26.08% in 2024, then soared by 209bps to 80.69% in 2025.
  • Business Quant data shows EBT Margin for SRPT at 80.69% in Q4 2025, 48.59% in Q3 2025, and 25.14% in Q2 2025.